A new drug for treating early-stage Alzheimer’s disease has been administered for the first time in Taiwan on an 83-year-old ...

The new medications are currently not covered by Taiwan’s health insurance system but are available to patients who can pay ...

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Our federal lawmakers should substantial and sustained investments for Alzheimer’s research funding and the dementia public ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...